The receptor interacting serine/threonine protein kinase (RIPK) family is comprised of seven members, all of which share a homologous kinase domain with varying intermediary and C-terminal domains (►Fig. 1A). These unique nonkinase domains differentiate the proteins and largely dictate their function.
associated with familial and sporadic Parkinson's disease and Crohn's disease. 8, 9 In general, the functions of RIPK4-7 are poorly understood. For the purpose of this review, we will focus on the most studied RIP kinases in the liver: RIPK1 and RIPK3. RIPK1 was first described as a FAS receptor interacting protein and as a mediator of cell death. 10 The structure of RIPK1 and whether it is in a kinase active conformation or not dictates its function. When ubiquitinated, RIPK1 is in closed conformation and forms a platform that facilitates congregation of multiprotein complexes resulting in NFκB and mitogen-activated protein kinase (MAPK) activation. 11, 12 In its kinase-active form, RIPK1 recruits RIPK3 to its RHIM domain initiating cell death pathways. RIPK1 is constitutively expressed in most tissues. However, stress signals, DR ligands, or T cell activation can induce the protein.
1,10 RIPK3 was described subsequent to RIPK1 in 1999 as a novel protein with an N-terminal kinase domain that was closely homologous with RIPK1s. 7 RIPK3 was shown to contain the RHIM domain enabling its binding to RIPK1, and RIPK3 overexpression was shown to induce apoptosis.
7
RIPK3 tissue distribution is not uniform and the protein is difficult to detect in hepatocytes under basal conditions.
7,13
In fact, the presence of RIPK3 in the liver and whether it is induced and in which models is a matter of intense debate.
14 Interestingly, unlike RIPK1 À/À mice which die within 3 days of birth, 11 RIPK3 À/À mice showed no phenotype. 15 However, kinase-dead RIPK1 knock-in mice are viable and fertile, while some kinase-dead RIPK3 mice (D161N mutant) die at embryonic day 11.5 5 (►Fig. 1B). Both proteins can mediate apoptosis through DRs. When caspase-8 is inhibited or absent, TNF can result in an alternative cell death subroutine termed necroptosis, which is regulated in execution, and necrotic in morphology. 16 Since the discovery that RIPK1 and RIPK3 mediate the TNF death signal to activate the necroptosis effector mixed lineage domain like (MLKL), these kinases have been largely studied in the context of necroptosis. 17 These signaling events can occur downstream of various DRs (TNF, FAS, TRAIL, TLR, etc.) with some variations. For simplicity, we will focus on the extensively studied TNF signaling pathway.
18-21

RIPKs and Apoptosis
TNF is a potent inducer of cytokines and inflammation. TNF activation can also result in the activation of caspases, DNA fragmentation, chromatin condensation, plasma membrane blebbing, cell shrinkage, and ultimately formation of apoptotic bodies. 22 Binding of TNF to TNFR results in the formation of an intracellular signaling protein complex called The aspartate (D) at position 161 in the catalytically important DFG (Asp-Phe-Gly) motif of the kinase domain of RIPK3 is mutated to an asparagine (N), rendering the protein catalytically inactive or "kinase-dead." The mice generated with this mutation are not viable and die at E11.5. RIPK3-K51A: The lysine (K) at position 51 on the ATP-binding pocket is mutated to an alanine (A) resulting in "kinase-dead" RIPK3. 
RIPKs and Necroptosis
Despite being a critical member of the DR-induced Complex-I and participating in apoptosis, RIPK1's claim to fame is due to its link with the more recently described cell death subroutine, necroptosis. Necroptosis occurs in certain cell types when TNF binds toTNFR in the presence of a pan-caspase inhibitor (þ/À an IAP antagonist). 36 One intriguing aspect of the relationship between RIPK1 and RIPK3 lies in the observation that in addition to collaboration with RIPK3 to promote cell death, RIPK1 can inhibit RIPK3 under certain conditions. RIPK1-specific knockout in intestinal epithelium or keratinocytes resulted in spontaneous RIPK3-mediated cell death and inflammation. 54, 55 The precise mechanism by which this occurs remains unknown.
RIPKs and Inflammation
While RIPKs were initially described as mediators of cell death and survival, emerging evidence indicates a necroptosis-independent role for the RIPKs in inflammation (►Fig. 3). 56 The most obvious evidence for this lies in the relationship between RIPK1 and NFκB, the main transcription factor for the expression of inflammatory genes. Ubiquitinated RIPK1's scaffolding function mediates NFκB activation downstream of TNF. Although RIPK1 seems to be dispensable for NFκB activation, some studies have suggested decreased expression of NFκB responsive genes without RIPK1. 57-59 RIPK1 and RIPK3 can participate in inflammatory pathways such as TLR signaling, cytokine production, NOD-like receptor protein 3 (NLRP3), and inflammasome activation independent of MLKL and their role as mediators of necroptosis. [60] [61] [62] The effect of RIPK1 and RIPK3
in inflammation was initially assumed to be due to the inflammatory nature of necroptotic cell death from MLKL-mediated plasma membrane rupture and release of intracellular immunogenic molecules. However, there is accumulating evidence that the RIPKs directly influence inflammation. An example is in the TNF-α-induced protein 3 (Tnfaip3)/A20 global knockout mouse. A20 À/À mice have systemic inflammation resulting in cell death. Deletion of RIPK3 or a catalytic-inactive RIPK1 significantly delays mortality in these mice, while MLKL deletion does not. 63 Liver leukocytes isolated from RIPK3 À/À mice and stimulated by α-galactosylceramide (α-GalCer) showed significantly reduced production of cytokines (TNF, interleukin-4 [IL-4], and interferon gamma [IFN-γ]) compared with wild type (WT) cells suggesting a role for RIPK3 in natural killer T cells (NKT) cytokine production. 64 Macrophages lacking cIAPs secret larger quantities of proinflammatory TNF and IL-6 which required RIPK1 and RIPK3, but not MLKL.
Inflammasome-dependent cell death or pyroptosis is characterized by the assembly of a multiprotein complex (NLRP3-ASC-caspase-1), resulting in activation of caspase-1 and release of the proinflammatory cytokines IL-1β and IL-18.
56
RIPK3 can activate caspase-1 and promote IL-1β cleavage, thereby contributing to inflammatory cytokine production. 61 reviewed extensively. 56, 71, 72 The RIPKs role in the inflammasome and in necroptosis may not be mutually exclusive and there may be cross-talk between the two pathways. 56 Therefore, a growing body of evidence suggests that the RIPKs are multifunctional proteins with prominent roles independent of their actions as cell death mediators (►Fig. 3). These nonnecroptotic properties should be taken into account when interpreting experimental findings.
14
RIPKs in the Liver
Cell death is an important driver of liver disease and both apoptosis and necrosis occur in the liver with apoptosis being the more common death pathway. RIPK3 is difficult to detect in freshly isolated hepatocyte, it is robustly expressed in the nonparenchymal cell (NPC) fraction, making it possible that necroptosis occurs in certain cell types in the liver. 78 A RIPK3-independent model for necroptosis in hepatocytes has been suggested, and since MLKL is clearly present in the liver, it is hypothesized that other MLKL activators exist.
79,80
RIPKs in APAP Toxicity and Hepatocyte Death RIPK1 was the first family member studied in liver disease due to the availability of nec-1, the RIPK1 kinase inhibitor which was shown to protect against necrotic cell death in multiple organ systems. 41, 42 Using nec-1 multiple investigator demonstrated a survival benefit against acetaminophen (APAP)-induced liver injury in mice and in hepatocytes in vitro. [86] [87] [88] [89] [90] Unlike the consistent and reproducible results with nec-1, RIPK3′s role in APAP and whether necroptosis occurred in the liver became the source of controversy.
14,78
Since the cell death mode in APAP is largely necrotic, the abrogation of injury with nec-1 was initially interpreted as inhibition of necroptosis. However, nec-1 is neither specific to RIPK1 nor necroptosis. 38 Nec-1 was discovered to be identical to the indoleamine 2,3-dioxygenase (IDO) inhibitor methyl-thiohydantoin-tryptophan (MTH-Trp). 91 IDO is a potent immunomodulator and is the rate-limiting step of tryptophan catabolism and it has been shown to regulate pathways that lead to pro-and anti-inflammatory cytokine The Receptor Interacting Protein Kinases in the Liver Dara 77 production. Therefore, additional evidence was needed regarding the role of RIPK1 in APAP-induced liver injury.
91
Using an antisense oligonucleotide knockdown approach, we observed that RIPK1 knockdown in liver protected significantly from APAP-induced cell death and provided a survival benefit to mice. In keeping with the controversial reports on this matter, RIPK1's role in APAP toxicity was soon challenged. 92 The off target effects of nec-1 combined with fact that necroptosis requires the participation of RIPK3 and MLKL led us to explore APAP toxicity in RIPK3 and MLKL knockout mice to settle the question of APAP-induced necroptosis in the liver. 78 Previously, it was reported that RIPK3 À/À mice were protected against APAP at early (6 hours) but not late (24 hours) time points. 88 We were unable to detect any difference in liver injury from RIPK3 À/À mice compared with WT animals at either time.
78
However, knockdown of RIPK1 in RIPK3 À/À mice afforded a significant protection, suggesting that RIPK1 was functioning independent of RIPK3 and necroptosis to protect against APAP toxicity.
78 To confirm this, we used MLKL À/À mice and were unable to detect any attenuation of APAP-induced cell death in MLKL À/À mice. 78 These results were later independently confirmed by others. 79 Therefore, the mere participation and even induction of the RIPKs in any disease model does not indicate that the cell death subroutine is necroptosis. In fact, many of the studies in different models and organ systems showing protection using nec-1, RIPK1 kinase dead, and RIPK3 À/À mice were not reproducible in MLKL À/À mice, pointing to the multifactorial and nonnecroptotic functions of these proteins.
63
RIPKs in Immune-Mediated Liver Injury Models
Compounds that activate the immune system such as concanavalin A (ConA) and α-GalCer are widely used substitute models for human autoimmune hepatitis. Unlike autoimmune hepatitis which is mainly adaptive immune mediated, these compounds generate an innate immune response. ConA, a plant lectin, activates CD4þ T cells, NKT cells, Kupffer cell (KC), and macrophages to induce an immune-mediated hepatitis. 93 The mode of cell death in ConA has been a source of debate, but the preponderance of the evidence suggests it is a necrotic subroutine (no protection by caspase inhibition), although some apoptosis may occur in the early phases of injury. be TNF. 96 The necrotic mode of cell death combined with the dependency on DR signaling has led multiple investigators to study necroptosis in ConA-induced liver injury. Pretreatment of nec-1 was suggested by some to markedly protect against ConA. 97-99 RIPK1 kinase inhibition has been proposed to result in decreased poly ADP-ribose polymerase-1 activation, and decreased IL-33 suggesting that RIPK1 is an upstream mediator of these signaling events in ConA.
97,98
However, in vivo RIPK1 knockdown in the liver (with antisense) resulted in exacerbated injury and increased mortality from ConA which was almost completely prevented by zVAD-fmk. 57 Using RIPK1 kinase dead knock-in mice (Ripk1-K45A) and nec-1s, Filliol et al have reported that RIPK1 kinase activity drives liver injury induced by ConA, as shown by reduced levels of serum transaminases and improved histology. 100 Interestingly, RIPK1 liver-specific knockout RIPK1-LPCKO (liver parenchymal cell knockout) resulted in more pronounced injury and higher alanine aminotransferase (ALT). In agreement with the aforementioned study, the cell death mode in these RIPK1-deficient hepatocytes was caspase-dependent apoptosis. 100 Furthermore, RIPK1 deletion in parenchymal cells resulted in a more robust inflammatory response. This enhanced sensitivity was TNF mediated as treatment with etanercept, which neutralizes TNF, protected against ConA. 100 These studies elucidate the complexity with the RIPK1 protein as inhibiting its kinase and platform activities resulted in alternative outcomes. In contrast to the studies reporting benefit with RIPK1 kinase inhibition(genetically or using nec-1), others have observed a worsening of injury and increased mortality (up to 50%) with the more specific nec-1s. 87 Interestingly, these same investigators reported that despite aggravation of liver injury with nec-1s, a modest attenuation was observed in RIPK3 global knockouts. 87 Kang et al have also reported that ConA injury is attenuated in RIPK3 À/À mice. 64 However, the contribution of RIPK3 to ConA has been challenged by two independent reports indicating no difference in outcomes of liver injury in RIPK3 À/À compared with WT mice. 79,101 Interestingly, Gunther et al were unable to detect any RIPK3 in hepatocytes and failed to detect an induction or increase in transcripts following ConA treatment. 79 However, despite no role for RIPK3, they reported less liver injury in both MLKL À/À mice and in nec-1s pretreated mice with ConA, suggesting an alternative MLKL activation pathway in hepatocytes.
79
Further exploration of this alternative, noncanonical necroptotic pathway to MLKL activation is warranted. The glycolipid α-GalCer which is a specific and potent activator for invariant NKT has also been used to study immune-mediated liver injury. 57 This model resembles the ConA model, but is relatively less severe and restricted to NKT cells, innate immune cells uniquely abundant in the liver. Using both α-GalCer and ConA models, Kang et al have reported attenuation of liver injury in RIPK3 -\-with less cytokine (TNF, IL-4) and IFN-γ expression. RIPK3 in bone marrow (BM) cells was essential as ConA-induced liver injury was significantly attenuated in the WT animals that were transplanted with RIPK3 À/À BM. This protective effect was suggested to be due to the effect of RIPK3 on cytokine production from NKT cells deficient in RIPK3 and not due to the prevention of hepatocyte necroptosis. 64 Contrary to the findings by Kang et al, we found no difference in liver injury between global RIPK3 À/ À , MLKL À/À mice and strain matched controls treated with α-GalCer. 57 However, knockdown of RIPK1 markedly aggravated α-GalCer-induced hepatitis and resulted in 90% post-treatment mortality as early as 6 hours post-α-GalCer. 57 Accompanying the exacerbated liver injury, RIPK1 knockdown significantly increased serum levels of proinflammatory cytokines and chemokines (TNF and IFN-γ) 6 hours postinjection correlating with increased inflammatory cell infiltration. 57 The liver cell death was accompanied by caspase-3 activation and inhibited by TNF neutralization and pan-caspase inhibitors without a switch to necroptosis. 57 This increased sensitivity to TNF was not seen in RIPK1 kinase dead D138N mice or with nec-1 and seems to be due to the scaffolding functions of RIPK1.
57
Increased sensitivity of hepatocytes lacking RIPK1 to TNFmediated apoptosis has been reported using LPS and unmethylated CpG oligodeoxynucleotide (CpG-DNA) to induce liver injury as well. 57, 102 In RIPK1 knockdown livers, low-dose LPS resulted in massive hepatocyte apoptosis.
This injury is thought to be mediated by macrophage-produced TNF as macrophage depletion using clodronate or the use of a TNF neutralizing antibody can rescue from liver injury. 57, 102 While certain aspects of these studies, namely the effect of RIPK3 deletion and RIPK1 inhibitors in immunemediated hepatitis has been controversial, a common theme that becomes evident is that deletion of RIPK1 aggravates immune-mediated liver injury by sensitizing hepatocytes to TNF-mediated apoptosis. The discrepancies in many of these reports could be minimized by using standard dosing regimens and appropriate controls (especially when DMSO is the vehicle). Additionally, interpretation of effects in animal models where littermate controls are not used should be done with caution.
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RIPKs in Fatty Liver Disease and Alcoholic Liver Disease
ASH and NASH are major public health problems and leading causes of liver-related mortality worldwide and in the United States. 103, 104 These distinct disease entities share many common features such as steatosis, Mallory bodies, inflammation, parenchymal fibrosis, and hepatocyte injury, leading to cell death. In both entities, a major driver of disease progression is cell death with apoptosis as the main subroutine. 75, 105 This is demonstrated by the fact that caspase-8 liver-specific KO (casp8-LKO) or caspase inhibition greatly protects against steatohepatitis without a switch to necroptosis in NASH. [106] [107] [108] Studies examining the role of the RIPK proteins in NASH have yielded contradictory results. This may be partly due to the various models employed to induce NASH in rodents. Studies using diets deficient in methionine and choline (MCD) were commonly used to induce steatohepatitis in mice. However, MCD has fallen out of favor as mice on these diets, lose weight, and do not exhibit the metabolic syndrome phenotype despite developing steatohepatitis. 109 Using the MCD model, an increase in RIPK3
protein as early as 2 weeks has been reported. 84 In contrast to 14 In contrast to reports of amelioration of injury in RIPK3 À/À using the MCD diet, using the Western type high-fat diet (HFD) mice lacking RIPK3 exhibited significantly worse steatosis, fibrosis, and inflammation compared with WT mice. 82 The WT mice in this study expressed no basal RIPK3 or pMLKL, but after 12 weeks on the HFD both proteins increased in the fatty liver by immunohistochemistry. 82 However, despite the high expression of pMLKL, these mice had very little injury and cell death. 82 Further complicating matters were the observation that RIPK3 À/À mice exhibit glucose intolerance at baseline on a chow diet. 82 The role of RIPK3 in alcoholic liver injury using the Lieber-DeCarli model of alcohol feeding has been explored. 83, 111 In contrast to the HFD study, RIPK3 À/À mice on a Lieber-DeCarli alcohol diet had a modest attenuation of injury compared with WT controls. 83 The authors also reported increased RIPK3 protein immunostaining in human liver biopsy samples with alcoholic liver disease. 83 Another group recently studied the mode of cell death in LieberDeCarli model using caspase-8-LPCKO mice and reported increased apoptosis with caspase-8-LPCKO with no significant RIPK1, RIPK3, and MLKL induction. 111 The Gao-binge model of alcohol feeding has also been reported to result in increased RIPK3 protein. 81 The authors found lower transaminase elevations and decreased steatosis from global RIPK3 deletion, but no difference in inflammation and hepatitis. They could not detect a transcriptional change in RIPK3, and attributed the increased protein levels of RIPK3 to impaired hepatic proteasome function. 81 The contribution of necroptosis to cell death in NASH is arguable and apoptosis seems to be the predominant cell death pathway. 75 Studies using hepatocyte specific MLKL knockout and littermate controls are needed to settle the matter. However, given recent reports of insulin resistance in RIPK3 À/À mice, 82 it is compelling to imagine a necroptosisindependent contribution of RIPK3 to NASH pathogenesis.
RIPKs in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), the most common primary liver tumor, often occurs in the context of chronic inflammation. Cell death is both a consequence and a cause of liver inflammation and therefore a strong link exists between hepatocyte death and HCC development. The role of the RIPKs has been explored in a few models of HCC. 59, 112, 113 In the human hepatoma cell line HepG2 cells, deletion of RIPK1 or cFLIP sensitized to TRAIL mediated apoptosis.
114 Surprisingly, low RIPK1 expression which is seen in some human HCCs has been associated with a worse prognosis and decreased survival. 112, 115 Conditional deletion of the mitogen-activated protein 3 (MAP3)-kinase, TAK1, in liver parenchymal cells (TAK1-LPCKO) results in hepatic inflammation, cholestasis, fibrosis which leads to HCC. 116 These TAK1-LPCKO mice exhibited defective NF-kB activation, increased spontaneous apoptosis, and increased RIPK3 protein expression. TAK1-caspase-8-LPCKO resulted in less injury and less caspase-3 cleavage without a switch to necroptosis. 116 The combination of global RIPK3 knockout with TAK1-LPCKO resulted in less necrosis, less cholestasis, and decreased ALT. At 38 weeks TAK1-caspase-8-LPCKO did not exhibit any tumors, while TAK1-LPCKO-RIPK3 À/À mice exhibited a massive tumor burden suggesting a role for RIPK3 in modulating hepatocyte apoptosis.
116
TAK1LPCKO-RIPK3 À/À mice had increased JNK activation and the addition of the JNK inhibitor significantly decreased hepatocytes proliferation (Ki67 and cyclin D1 levels).
116 NEMO liver parenchymal cell knockout (NEMO-LPCKO) results in hepatitis, hepatocyte apoptosis and HCC, suggesting a tumor suppressor function of NF-kB signaling in the liver. 117 The development of hepatitis and HCC in NEMO-LPCKO mice is triggered by FADD-and caspase-8-dependent apoptosis. Surprisingly NFKB-LPCKO mice, which lack all subunits in the liver parenchymal cells, have a much milder phenotype compared with NEMO-LPCKO suggesting that NEMO has NF-kB-independent prosurvival functions in hepatocytes. 113 The role of RIPK1 in mediating cell death from the NEMO-LPCKO mice has been explored using a genetic kinase dead RIPK1 knock-in mouse (D138N). 113 The addition of the kinase dead RIPK1 to the NEMO-LPCKO strongly inhibited hepatocyte death, prevented liver damage and HCC development. In contrast, the global deletion of RIPK3 À/À in the NEMO-LPCKO did not prevent these outcomes, suggesting that RIPK3/MLKL-driven necroptosis does not play an important role in this model.
113
Further supporting this was the fact that the dying hepatocytes stained positively for cleaved caspase-3 and ablation of caspase-8 or FADD inhibited cell death indicating RIPK1 kinasedependent apoptosis as the cell death subroutine. The expression of kinase-inactive RIPK1 fully restored the expression of cFLIP and partly normalized the expression of TRAF2 and cIAP1 proteins in the NEMO-deficient livers. However, RIPK1 ablation in LPC using RIPK1 floxed mice could not prevent the death of NEMO-deficient hepatocytes showing that kinaseindependent platform properties of RIPK1 are required to prevent hepatocyte apoptosis (this was prevented with the additional deletion of TRADD). 113 FADD and caspase-8 coimmunoprecipitated with RIPK1 suggesting that NEMO prevents formation of a RIPK1/FADD/Casp8 complex and that in the absence of NEMO RIPK1 mediates hepatocyte apoptosis via its kinase activity through this complex. In a recent report, genetic deletion of RIPK1 in parenchymal cells (RIPK1-LPCKO) had no spontaneous phenotype. However, when exposed to LPS/TNF these mice exhibited enhanced apoptosis due to the proteasomal degradation of TRAF2 leading to caspase-dependent cell death. 112 The mode of cell death was caspase-8-dependent apoptosis as the additional knockout of caspase-8 in these mice completely rescued the phenotype. 112 Unlike the RIPK1-LPCKO, inhibiting the kinase activity of RIPK1 genetically or pharmacologically did not sensitize to TNF-mediated cell death suggesting the platform function of RIPK1 is instrumental in cell survival. Interestingly like RIPK1-LPCKO, the TRAF2-LPCKO did not have a spontaneous phenotype but the double KO of RIPK1/TRAF2 resulted in hepatitis, impaired NFkB activation, and caspase-8-dependent apoptosis and HCC.
112
In this study, human liver HCC samples higher expression of RIPK1 and TRAF2 was associated with a significant survival benefit and low expression of these proteins predicted a worse prognosis. 112 In contrast, another study from China has reported increased RIPK1 expression in HCC samples as a poor prognostic indicator after resection. 118 Patients expressing more RIPK1 by immunostaining of tumor were more likely to have advanced stage, intrahepatic metastasis, and portal vein invasion. Interestingly, patients with increased RIPK1 in HCC were more likely to be HBV infected.
118
Van et al have used the diethylnitrosamine (DEN)-induced HCC model in RIPK1-LPCKO mice and have also observed increase in apoptosis with RIPK1 deletion and reduction in tumor size. 59 Interestingly, while ablation of either RIPK1 or
RelA in liver parenchymal cells did not cause spontaneous liver pathology, mice with combined deficiency of RIPK1 and RelA in LPCs showed increased hepatitis, increased hepatocyte apoptosis (cleaved caspase-3), and developed spontaneous chronic liver disease and cancer. 59 Lack of RIPK1 kinase activity did not inhibit DEN-induced liver tumor formation, confirming that kinase-independent functions of RIPK1 promote carcinogenesis in a TNFR1-dependent manner. 59 An interesting finding here was that unlike previous studies, RIPK1-LPCKO resulted in impaired NFκB signaling and reduction in the TNF-induced expression of A20, baculoviral IAP repeat-containing 3 (Birc3), nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor-α (Nfkbia), and TNF. 59 It has now been shown in multiple models that knockdown and knockout of RIPK1 in vivo sensitizes hepatocytes to TNF-mediated apoptotic cell death. 
RIPKs in Other Liver Diseases
The contribution of the RIPKs to cholestatic and viral liver disease is less extensively characterized. RIPK1 but not RIPK3 deletion completely rescues the growth retardation, ductopenia, and cholestatic phenotype of liver parenchymal cellspecific deletion of the IKKα/β subunits (IKKα/β-LPCKO).
115
Despite ductopenia and ongoing injury, no HCC developed in the IKKα/β-LPCKO livers suggesting a failure of cholangiocyte proliferation. Staining for Ki-67 revealed increased proliferation in the combined IKKα/β-LPCKO/RIPK1 KO compared with IKKα/β-LPCKO. 115 The authors proposed that RIPK1 is the direct phosphorylation target of the IKK subunits and functions as an antiproliferative protein in cholangiocyte homeostasis. 115 The mode of cell death in this model was proposed to be a combination of apoptosis and necrosis without a significant contribution from necroptosis as RIPK3 À/À did not affect the phenotype. 115 The Receptor Interacting Protein Kinases in the Liver Dara 81
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RIPK1 ablation in liver parenchymal cells. Furthermore, the effect of RIPK1 in the immune cells and nonparenchymal liver cells in these injury models has not been fully established.
14 RIPK3′s role in the liver has been quite controversial. Although RIPK3 is most known as the kinase-activating MLKL for necroptosis execution, RIPK3 can also mediate apoptosis. Mutant kinase-inactive RIPK3D161N protein and RIPK3 small molecule inhibitors promote apoptosis, due to the induction of a conformational change in RIPK3 resulting in RIPK1-mediated caspase-8 recruitment.
5,37
Whether necroptosis occurs in liver disease and in hepatocytes in particular is controversial. 14 However, increased expression of RIPK3 in both animal models of acute and chronic liver injury and human liver diseases has been suggested by some investigators, but not all. [81] [82] [83] [84] [85] 87, 119 In one model, due to a lack of increase in RIPK3 messenger ribonucleic acid, impaired proteasome function was implicated as the cause of increased RIPK3. 81 Much of the work on the RIPKs was done by immunostaining of liver tissue and most investigators have interpreted increased RIPK3 staining as the "induction of necroptosis" bringing up the issues of specificity of these stains on injured liver, and the quality of the reagents used. 14 In addition, most genetic knockout studies use complex embryonic multiprotein knockout models which could result in unforeseen compensatory biologic consequences and complicate interpretation of data and extrapolation to human physiology. Since these critiques are universal limitations of experimental models, multiple scientific approaches and more consistent findings by independent laboratories are necessary to draw firm conclusions regarding RIPK3 and necroptosis in the liver. We have been unable to detect RIPK3 in diseased human livers (unpublished data). In mice, we were only able to detect RIPK3 in the NPC fraction of the liver including immune cells and endothelial cells and others have confirmed this data. 78, 79 However, MLKL is robustly expressed.
A few key points and open questions remain that will guide future research in the field. Why is MLKL present in hepatocytes in the absence of RIPK3 and what other protein(s) can activate it? What are the non-necroptosis functions of RIPK1 and RIPK3 in the liver? What is the role of the RIPKs in the nonparenchymal liver cells? Given the heterogeneity of the liver and its diverse cell population, a more detailed examination of the effect of the RIPKs in the liver in a cell-specific manner should be undertaken. It is evident more than ever that non-necroptotic functions of the RIPKs in the liver (including apoptosis) may contribute to some of the findings in liver disease models. It is also important to consider that the cell death functions and noncell death/ inflammatory functions of the RIPKs may not be mutually exclusive. Finally, the most pressing clinical issue remains, which is to understand if necroptosis occurs with an intact apoptotic machinery and in the presence of caspase-8 in the physiologic setting or if activation of necroptosis is a potential complication of the use of caspase inhibitors therapeutically in human liver disease. There is still much to be learned about the functions of the RIPKs and future studies will shed some light on the complex biology of these multifunctional proteins.
Main Concepts and Learning Points
• RIPK1 and RIPK3 participate in both apoptotic and necroptotic cell death and this is largely context dependent.
• RIPK1 and RIPK3 have cell death-independent functions.
• RIPK1 knockdown and knockout sensitizes hepatocytes to apoptotic cell death in TNF/DR-mediated cell death models, indicating its scaffolding function mediates hepatocyte survival.
• RIPK3 is undetectable in hepatocytes under basal conditions; however, it may be induced in certain diseases.
• Whether necroptosis occurs in hepatocytes is unclear.
• The contribution of RIPK1 and RIPK3 in various liver disease models has been examined and is discussed. 
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